GGrantIndex
← Search

Cell Imaging Facility

$143,123P30FY2017CANIH

Northwestern University At Chicago, Evanston IL

Investigators

Linked publications, trials & patents

Trial NCT07639528Trial NCT07594626Trial NCT07594548Trial NCT07290543Trial NCT07261657Trial NCT07178301Trial NCT07169617Trial NCT07050186Trial NCT07042919Trial NCT06959641Trial NCT06813898Trial NCT06723457Trial NCT06630416Trial NCT06571734Trial NCT06499870Trial NCT06410248Trial NCT06327477Trial NCT06247540Trial NCT06244004Trial NCT06242834Trial NCT06184750Trial NCT06164275Trial NCT06137651Trial NCT06062498Trial NCT06060587Trial NCT06022822Trial NCT05879250Trial NCT05852041Trial NCT05802186Trial NCT05744739Trial NCT05733000Trial NCT05620771Trial NCT05576896Trial NCT05545150Trial NCT05453799Trial NCT05419011Trial NCT05411107Trial NCT05236036Trial NCT05202782Trial NCT05093387Trial NCT04931017Trial NCT04910425Trial NCT04795869Trial NCT04767984Trial NCT04753216Trial NCT04576104Trial NCT04550481Trial NCT04250051Trial NCT04227028Trial NCT04200443Trial NCT04049227Trial NCT04047706Trial NCT04033432Trial NCT04009044Trial NCT03854474Trial NCT03812562Trial NCT03742258Trial NCT03723915Trial NCT03704714Trial NCT03513484Trial NCT03317405Trial NCT03278925Trial NCT03226249Trial NCT03213041Trial NCT03146650Trial NCT03077828Trial NCT03070002Trial NCT03061188Trial NCT03048500Trial NCT03044730Trial NCT03036930Trial NCT03020017Trial NCT02993159Trial NCT02968810Trial NCT02965703Trial NCT02901899Trial NCT02892734Trial NCT02871323Trial NCT02861040Trial NCT02847559Trial NCT02837029Trial NCT02819804Trial NCT02808143Trial NCT02805868Trial NCT02794883Trial NCT02774681Trial NCT02743364Trial NCT02720484Trial NCT02694809Trial NCT02536794Trial NCT02530619Trial NCT02530502Trial NCT02530125Trial NCT02481310Trial NCT02365480Trial NCT02357810Trial NCT02314156Trial NCT02242097Trial NCT02237183Trial NCT02232516

Abstract

PROJECT SUMMARY (See instructions): State-of-the-art imaging technologies are powerful tools that can be leveraged to study various cellular and molecular mechanisms in cancer progression and how tumor cells interact with the tumor microenvironment. The Cell Imaging Facility provides imaging modalities that cover the range from single molecule microscopy to whole animals, and from brightfield, to fluorescence and bioluminescence imaging. The Cell Imaging Facility offers bioluminescene/fluorescence in vivo imagers, microprobe lens-driven intravital microscope, multiphoton microscope, various fluorescence microscopes including macroview stereoscope, high content slide scanner and tissue cytometer, spinning disk confocal microscope, multispectral confocals with resonant scanner, integrated incubator microscope, structured illumination super-resolution microscope, laser microdissection system, and transmission electron microscope with 3D tomography capability. Collectively, this vast instrument portfolio offers core services in advanced microscopy on single molecules, macromolecular networks, live cells, FRET, FRAP, FLIP, photoconversion, TIRF, large tissue sections in bright field and fluorescence, specific tissue procurement, intravital imaging, and whole animal imaging. This creates a unique environment in which investigators can design workflow-based correlative experiments to study their cancer specimens all the way from whole animals to single molecules. This wide-ranging microscopy instrumentation and services is fully supported by the technical expertise of a team that has been consecutively recognized by the Northwestern University Office for Research as Outstanding Core for multiple years. The team is led by the facility director. Dr. Teng-Leong Chew. Dr. Chew is an expert in advanced live cell imaging, and has pioneered the development of several biosensors and imaging applications. Together the team provides active training and educational outreach in personalized instrument training, experimental consultation, seminars, journal clubs, hands-on workshops, as well as image analysis and programming boot camps. This 24-hr facility serves more than 180 labs throughout the university, and we maintain our leadership position in novel imaging technologies through a two-pronged approach: (i) aggressive and successful effort in securing shared instrument funds. We have added ten instruments over $300K since the last CCSG cycle; (ii) leveraging our expertise to attract leading manufacturers to establish beta test sites in the imaging center. These efforts have culminated in the facility being recognized by Nikon as one of only eight Nikon Imaging Centers in the world, allowing the cancer center to benefit immensely from the investment of Nikon's latest technologies. In 2012, we were selected by EuroBioimaging Consortium as the first American imaging center to join this trans-Atlantic multinational imaging network. These achievements place the Cancer Center uniquely at the forefront of cancer imaging technologies.

View original record on NIH RePORTER →